Brief: Sernova Announces First Two Patients Implanted With Cell Pouch In The Second Cohort Of Its U.S. Phase 1/2 Clinical Trial For Type 1 Diabetes
17/11/2022 12:50
Nov 17 (Reuters) - Sernova Corp SVA.TO :
* SERNOVA ANNOUNCES FIRST TWO PATIENTS IMPLANTED WITH CELL
POUCH™
IN THE SECOND COHORT OF ITS US PHASE 1/2 CLINICAL TRIAL FOR TYPE
1 DIABETES
* SERNOVA CORP - TRANSPLANTATION OF ISLETS INTO ENHANCED
10-CHANNEL CELL POUCH IS ANTICIPATED IN EARLY 2023
* SERNOVA CORP - COMPANY CONTINUES TO ANTICIPATE FIRST
INTERIM
SAFETY/EFFICACY DATA FROM SECOND COHORT IN 2023
* SERNOVA CORP - SECOND COHORT OF STUDY IS TO ENROLL UP TO
SEVEN
PATIENTS WITH INSULIN DEPENDENT T1D
Source text for Eikon: ID:nGNX34j8M9
Further company coverage: SVA.TO
Recent news on Sernova Biotherapeutics
See all newsBrief: Seraxis And Sernova Announce Appointment Of Former FDA Medical Officer Dr. Patricia Beaston As Chief Medical Officer Of Seraxis And Post Merger Betanova Biotherapeutics
Brief: Sernova Appoints Jonathan Rigby As Interim Chair
Brief: Sernova Biotherapeutics Provides Positive Interim Data From Ongoing Phase 1/2 Clinical Trial Of Cell Pouch Bio-Hybrid Organ In Patients Living With Type 1 Diabetes
Brief: Sernova Biotherapeutics Secures $4 Million Loan To Further Advance Its Clinical Development Plans
Brief: Sernova Biotherapeutics Inc Study Is On Track To Meet Key Clinical Trial Endpoints